A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.

The best current model of breast cancer evolution suggests that most cancers arise from certain premalignant lesions. We have identified a common (34%) somatic mutation in the estrogen receptor (ER)-alpha gene in a series of 59 typical hyperplasias, a type of early premalignant breast lesion. The mutation, which affects the border of the hinge and hormone binding domains of ER-alpha, showed increased sensitivity to estrogen as compared with wild-type ER-alpha in stably transfected breast cancer cells, including markedly increased proliferation at subphysiological levels of estrogen. The mutated ER-alpha exhibits enhanced binding to the TIF-2 coactivator at low levels of hormone, which may partially explain its increased estrogen responsiveness. These data suggest that this mutation may promote or accelerate the development of cancer from premalignant breast lesions.

[1]  J. Foekens,et al.  Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. , 1994, The American journal of pathology.

[2]  S. Fuqua,et al.  The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. , 1993, Cancer research.

[3]  P. Chambon,et al.  A highly conserved region in the hormone-binding domain of the human estrogen receptor functions as an efficient transactivation domain in yeast. , 1994, Gene.

[4]  P. O’Connell,et al.  Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. , 1999, Journal of the National Cancer Institute.

[5]  S. Fuqua,et al.  A role for estrogen-receptor variants in endocrine resistance , 1995 .

[6]  M. Stallcup,et al.  Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. , 1998, Molecular Endocrinology.

[7]  W. McGuire,et al.  Variant human breast tumor estrogen receptor with constitutive transcriptional activity. , 1991, Cancer research.

[8]  K. Horwitz,et al.  The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. , 1997, Molecular endocrinology.

[9]  P. O’Connell,et al.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.

[10]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[11]  J. Shine,et al.  Sequence and expression of human estrogen receptor complementary DNA. , 1986, Science.

[12]  S. Fuqua,et al.  An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. , 1997, Cancer research.

[13]  V. Giguère,et al.  Ligand-independent Activation of the Estrogen Receptors α and β by Mutations of a Conserved Tyrosine Can Be Abolished by Antiestrogens , 1998 .

[14]  A. Thor,et al.  Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas , 1996, Science.

[15]  D. Cox,et al.  An Analysis of Transformations , 1964 .

[16]  D. Edwards,et al.  The Steroid Receptor Coactivator-1 Contains Multiple Receptor Interacting and Activation Domains That Cooperatively Enhance the Activation Function 1 (AF1) and AF2 Domains of Steroid Receptors* , 1998, The Journal of Biological Chemistry.

[17]  K. Horwitz,et al.  Nuclear receptor coactivators and corepressors. , 1996, Molecular endocrinology.

[18]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[19]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.